Prexton Therapeutics rakes in $10 mln
Prexton Therapeutics, a Swiss biopharmaceutical company focused on treating CNS conditions, has raised $10 million in Series A funding. Sunstone Capital and Ysios Capital led the round with participation from previous backer MS Ventures. In addition to the funding, Andreas Segerros of Sunstone and Raúl Martín-Ruiz of Ysios, will join Prexton's board of directors.
24 February 2015•4 mins read
